

INTERNATIONAL DIVIDEND **STRATEGY**

FACT SHEET

31/07/2022

Investment Objective

Rasameel's International Dividend strategy provides investors access to a diverse range of global dividend paying companies that potentially offer sustainable income and longterm growth.

Investment Manager

Rasameel Investment Company KSCC

Time Horizon Longterm

Inception Date 03/01/2021

Base Currency

USD

Benchmark Index

S&P Global Dividend Aristocrats ETF

Top Holdings

Company	Weight
TTE FP	6.78%
BP/ LN	6.67%
PFE US	6.07%
8058 JT	5.95%
ADIB UH	5.63%

Characteristics	Strategy
Dividend Yield	5.20%
TTM P/E	10.26
P/B	1.68
P/CF	5.34
Debt/Equity	0.79

Returns	Strategy	Benchmark		
MTD	2.92%	1.59%		
YTD	-11.75%	-2.75%		
ITD	3.34%	7.48%		

Risk Statistics - ITD	Strategy	Benchmark
Std. Dev	15.41%	11.71%
Downside Risk	11.83%	8.51%
MC VAR	-23.90%	-25.58%
BETA (ex-post)	0.97	1.00
Correlation	0.73	1.00
Sharpe Ratio	-0.44	-0.36
IR	-0.24	NA

Performance



Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	YTD	Benchmark
2022 (%)	-0.40	-4.14	-0.67	-3.01	2.47	-8.96	2.92						-11.75	-2.75
2021 (%)			5.73	2.04	3.65	-1.23	0.29	1.46	-2.66	2.41	-3.00	7.87	17.16	12.21


30 Day Top Contributers & Detractors


Contributers	Return	Cont.	Detractors	Return	Cont.
DRX LN	22.16%	1.06%	TTE FP	-3.69%	-0.28%
ADIB UH	21.20%	1.04%	PFE US	-2.90%	-0.18%
3M US	10.69%	0.25%	GILD US	-3.33%	-0.18%
HPE US	7.39%	0.24%	IBM US	-7.37%	-0.09%
BKG LN	13.94%	0.23%	SAN FP	-1.63%	-0.09%

Geographic Breakdown



Sector Breakdown





The performance shown above is gross of all fess and unaudited. Past performance is not indicative of future returns.

Disclaimer:

This document is prepared for promotional purposes. The performance reported above is of a model portfolio and is gross of fees and commisions. Rasameel Investment Company hereby undertakes that it does not disguise, diminish or obscure important items from the investment subject of promotion.

Warning:

The past performance of any investment or a product is not a reliable indicator of future results and it cannot be relied upon for investment decision making.



INTERNATIONAL DIVIDEND STRATEGY

FACT SHEET

31/07/2022

Comment

Rasameel's International Dividend Strategy outperformed its benchmark in July. The Strategy rose by 2.9% vs the benchmark's rise of 1.6%. On a YTD basis, the Strategy recouped some of its performance owing to losses in its Russian holdings, which are currently marked to zero. From a factor perspective, we continue to see the "Dividend" factor outperform other factors in turbulent markets like todays. Investors continue to see dividend playing stocks as a safe-haven amidst all the volatility from macro, geo-politics, earnings and growth concerns.

July saw global markets rebounding sharply despite aggressive central bank rate hikes, soaring inflation, energy disruption in Europe, a fresh property crisis in China and few signs of an end to the war in Ukraine. The S&P 500 climbed 9.1% while the MSCI world Islamic index rose 5.5%. While commodities in general performed well, Brent crude fell 4.2% over the month. As we highlight in our monthly outlook letter found here, we see July's sharp rebound as a bear market rally. Thus, we decided against chasing it.

In terms of contributors, **Drax Group (DRX LN)** delivered a 22% return over the month after announcing strong earnings. The stock saw several analyst upgrades following its earnings. **Abu Dhabi Islamic Bank (ADIB UH)** rose 21.2% over the month as the bank continues to ride the wave of economic recovery in the **UAE. 3M (3M US)** rose 10.7% over the month after beating analyst expectations in its most recent earnings release. **Hewlett Packard Enterprises (HPE US)** rose 7.4% in July. We continue to see strong demand in the server market and recent capex guidance from several companies suggest spending will continue to remain resilient. **Berkeley Group Holdings (BKG LN)** also reported strong earnings and the stock posted a 13.9% return for the month.

The detractors were largely concentrated within the healthcare sector which underperformed the market in July. Defensive sectors such as healthcare fell as the risk-on rally took steam post Fed announcement. However, given our outlook for the markets, we continue to see healthcare as a good sector to hold in 2022. Pfizer (PFE US), Gilead Sciences (GILD US) and Sanofi (SAN FP) fell 2.95, 3.3% and 1.6% respectively. With energy, Total energies (TTE FP) fell 3.7% in line with the fall in brent crude prices seen over the month. IBM (IBM US) fell 7.4% as management cited a weaker than expected outlook.

The international dividend strategy continues to remain diversified through sectors and geographies. Given that the strategy continues to hold defensive sectors such as utilities (12% weight), healthcare (24%), and consumer staples (7%), as well as a 4% position in cash, it should be relatively well insulated from recession risk compared to broad equity indices. The Strategy currently has a dividend yield of 5.2%.

Disclaimer

This document is not directed at or intended for use by any person resident or located in any jurisdiction where the distribution of such information is contrary to the laws of such jurisdiction, or such distribution is prohibited without obtaining the necessary licenses or authorizations. No representation or warranty, either express or implied, is provided in relation to the accuracy, completeness or reliability of the content. The information contained in this document is for promotional purposes only and should not be regarded by recipients as a substitute for the exercise of their own judgment. This document does not constitute a solicitation, an offer, or a recommendation to buy or sell any investment instruments, to effect any transactions, or to conclude any legal act of any kind whatsoever. The performance stated above is of a model account. Rasameel Investment Company hereby undertakes that it does not disguise, diminish or obscure important items from the investment subject of promotion.

Warning:

The past performance of any investment or a product is not a reliable indicator of future results and it cannot be relied upon for investment decision making.